about
Stereotactic body radiation therapy for liver metastasesStereotactic Ablative Radiotherapy (SABR) in inoperable oligometastatic disease from colorectal cancer: a safe and effective approach.Temozolomide combined with radiotherapy in the treatment of recurrent cranial meningioma previously treated with multiple surgical resections and two sessions of radiosurgery: a case report and literature review.Radiation therapy of anal canal cancer: from conformal therapy to volumetric modulated arc therapyMultimodality therapy approaches, local and systemic treatment, compared with chemotherapy alone in recurrent glioblastoma.Toxicity profile and early clinical outcome for advanced head and neck cancer patients treated with simultaneous integrated boost and volumetric modulated arc therapy.Hypofractionated Stereotactic Radiation Therapy in Recurrent High-Grade Glioma: A New Challenge.The role of stereotactic body radiation therapy (SBRT) in the treatment of oligometastatic disease in the elderlyVolumetric modulated arc therapy with flattening filter free beams for isolated abdominal/pelvic lymph nodes: report of dosimetric and early clinical results in oligometastatic patients.SBRT in unresectable advanced pancreatic cancer: preliminary results of a mono-institutional experience.Initial experience of hypofractionated radiation retreatment with true beam and flattening filter free beam in selected case reports of recurrent nasopharyngeal carcinoma.Volumetric modulated arc therapy for thoracic node metastases: a safe and effective treatment for a neglected disease.Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments.Liver metastases and SBRT: A new paradigm?Hypofractionated stereotactic radiation therapy in skull base meningiomas.Radical hypo-fractionated radiotherapy with volumetric modulated arc therapy in lung cancer : A retrospective study of elderly patients with stage III disease.Treatment: Outcome and Toxicity of Volumetric Modulated Arc Therapy in Oropharyngeal Carcinoma.Can Stereotactic Body Radiation Therapy Be a Viable and Efficient Therapeutic Option for Unresectable Locally Advanced Pancreatic Adenocarcinoma? Results of a Phase 2 Study.Are three weeks hypofractionated radiation therapy (HFRT) comparable to six weeks for newly diagnosed glioblastoma patients? Results of a phase II study.Outcome and toxicity profiles in the treatment of locally advanced lung cancer with volumetric modulated arc therapy.P13.03HYPOFRACTIONATED STEREOTACTIC RADIOTHERAPY (HSR) IN RECURRENT HIGH GRADE GLIOMA: A SAFE AND EFFECTIVE APPROACH.O2.02ROLE OF AN INTEGRATED IMAGING FOR TARGET VOLUME DEFINITION AND RADIOTHERAPY PLANNING IN PATIENTS WITH DIAGNOSED HIGH GRADE GLIOMA.Outcome Evaluation of HER2 Breast Cancer Patients with Limited Brain Metastasis.Variability in axillary lymph node delineation for breast cancer radiotherapy in presence of guidelines on a multi-institutional platform.Stereotactic body radiotherapy with flattening filter-free beams for prostate cancer: assessment of patient-reported quality of life.Maximize surgical resection beyond contrast-enhancing boundaries in newly diagnosed glioblastoma multiforme: is it useful and safe? A single institution retrospective experience.Investigation on the role of integrated PET/MRI for target volume definition and radiotherapy planning in patients with high grade glioma.Hypofractionated radiation therapy (HFRT) versus conventional fractionated radiation therapy (CRT) for newly diagnosed glioblastoma patients. A propensity score matched analysis.Stereotactic/hypofractionated body radiation therapy as an effective treatment for lymph node metastases from colorectal cancer: an institutional retrospective analysis.Outcome evaluation of patients with newly diagnosed anaplastic gliomas treated in a single institution.Clinical results of stereotactic body radiotherapy (SBRT) in the treatment of isolated local recurrence of pancreatic cancer after R0 surgery: A retrospective study.Role of stereotactic body radiation therapy for lung metastases from radio-resistant primary tumours.Hypofractionation with VMAT versus 3DCRT in post-operative patients with prostate cancer.P19.03 Randomized double arm phase III study to evaluate feasibility and safety of Gamma Knife radiosurgery versus Linac Based (Edge) radiosurgery in brain metastatic patients.P13.11 Outcome evaluation of oligometastatic patients with single, large brain metastases treated with gross total resection (GTR) followed by hypofractionated stereotactic radiosurgery (HSRS) on the tumor bed.Final results of a phase II trial for stereotactic body radiation therapy for patients with inoperable liver metastases from colorectal cancerClinical Outcome of Stereotactic Ablative Body Radiotherapy for Lung Metastatic Lesions in Non-small Cell Lung Cancer Oligometastatic PatientsNeoadjuvant Chemoradiotherapy with Volumetric-modulated Arc Therapy for Medium-distal Oesophageal and Gastro-oesophageal Junction CarcinomaThe challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT)Long-term local control achieved after hypofractionated stereotactic body radiotherapy for adrenal gland metastases: A retrospective analysis of 34 patients
P50
Q27008308-7C65CF32-8D86-4A2C-8AA5-B4108F32F3CCQ34196471-CA2456CB-D219-4543-B04D-13F9C1844547Q34349003-3AABE275-0520-4D3C-9FB7-E6A07F1C3EA1Q34584811-6CB24EB8-4A45-4670-8B0A-153EADE621B1Q35676452-5131A6BB-4B48-47FD-903F-AA7EB7822A9BQ36259231-5E0773ED-D0A2-472F-AB6D-E34BBCB35A83Q36482578-D2BB166F-7F9D-4EC9-97E4-A1BF7E2F3149Q36550917-1669E02E-0886-49D1-9FA2-DCE77B391894Q36552596-4244F45A-853D-483B-A5E4-1C771DBFA8B3Q37000899-BDEC5351-B552-42A0-B5FB-01262A65DA63Q37453956-DA1E84DE-6D2C-4C09-B220-93DE2093AF1AQ37619747-B7D4B787-BB83-4098-8FDF-BDAC657C62F7Q37723610-6B0CB0C8-807F-40F3-8572-D44EAD9FF8B2Q38677025-B8FB0D40-1509-4125-8C82-5D35BBE58E40Q39188313-1336812D-9A17-4E6F-9CCB-6030AA349D7FQ40346974-B0298953-5938-48CE-8CBC-DFC0B8F4FBA2Q40676821-94FFEAE6-6EAE-4639-A60E-C19223A94187Q42364897-F364EA09-27A7-4C81-836D-CBD9CC92C25EQ42366567-A480AF80-F319-47AD-8E6B-6408D14D27A7Q43677664-2954489B-AE77-4D28-8C0C-74E8640EDC1AQ46175516-210C6BD2-D214-47B5-AB21-5B4C90F40D01Q46886980-7B653546-65CC-4728-8A2D-91CF735663C4Q47350303-1F10059A-76CF-487B-9F4D-1CC8069550D6Q47367024-A1A98B6C-16F2-4463-BD49-8EC58ABEAADBQ48073893-A15D45CC-1CA6-45BE-9AAC-F8B0E9703EC4Q48156165-27F772B2-2FF6-495E-BB88-7A32FF3D8E11Q48488244-B37CB784-4697-4844-969B-3176E3D42ED1Q50124280-7C1927DC-C48A-4EBB-8359-E0185443FCD0Q50225656-8F2CE5BE-CA49-4393-9A56-EF66C0525BE2Q50526883-52CAB2EA-2170-4DFE-88B8-323AC0ACDBCEQ52953584-4082F60C-59B6-4A60-B52C-0D2F8A59BE9EQ53748913-624EE1DE-6F4E-467E-BD8F-BE66E65D57DDQ54766488-E3BF7CA5-6881-4C63-B34D-E186F43DE621Q54978051-3AEA13B7-5FD6-458F-A1EE-20A774217A92Q55001666-60E1C67E-10F9-48D4-B2C7-80690E35109BQ61054503-3FF93641-AB63-4683-91E2-B8AA39B4687BQ61986469-7368FB79-8344-49D9-8280-CCFF2A23649BQ61986479-EE7C9C17-73F2-4174-8B0B-EDF0969715A7Q61986481-354A8375-A0FE-46BA-BF6C-84A877A181CAQ61986529-127ABFA2-1C74-46E4-ACC1-45F8633C2D6C
P50
description
onderzoeker
@nl
researcher ORCID ID = 0000-0002-1765-863X
@en
name
Elena Clerici
@ast
Elena Clerici
@en
Elena Clerici
@es
Elena Clerici
@nl
type
label
Elena Clerici
@ast
Elena Clerici
@en
Elena Clerici
@es
Elena Clerici
@nl
prefLabel
Elena Clerici
@ast
Elena Clerici
@en
Elena Clerici
@es
Elena Clerici
@nl
P106
P21
P31
P496
0000-0002-1765-863X